trimethoprim--sulfamethoxazole-drug-combination and Leishmaniasis--Visceral

Seven cases of visceral leishmaniasis are reported, whose epidemiologic, clinical, laboratory, evolutive and therapeutical features are presented. Latest findings are described with reference to laboratory tests and new recent possibilities of therapy.

Topics: Antimony; Child; Child, Preschool; Drug Combinations; Female; Humans; Infant; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Metronidazole; Organometallic Compounds; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

In an attempt to find an orally effective drug against kala-azar, ethambutol alone, ethambutol plus INH, INH plus rifampicin, co-trimoxazole and metronidazole were tried in the treatment of 70 patients of Indian kala-azar. Ethambutol and ethambutol plus INH were totally ineffective. INH and rifampicin were tried in 10 cases; in three there was some clinical improvement but all relapsed and were cured with sodium stibogluconate. Co-trimoxazole reduced fever in four out of 20 cases, but all relapsed within 2 months. In one case the general health was well maintained but the splenic aspirate contained a large number of parasites and there was no regression in the size of the spleen. The patient was ultimately cured with sodium stibogluconate. Metronidazole orally or intravenously was not effective. It is suggested that, as these drugs are ineffective, a search for an oral substitute to sodium stibogluconate should continue.

Topics: Antiprotozoal Agents; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Leishmaniasis, Visceral; Male; Metronidazole; Random Allocation; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination

Currently, no licensed vaccine is available for human visceral leishmaniasis (VL), a fatal disease caused by the protozoan parasite Leishmania donovani. Two of our live attenuated L. donovani vaccine candidates, either deleted for Centrin1 (LdCen1

Topics: Animals; Biomarkers; Humans; Leishmania donovani; Leishmaniasis, Visceral; Proteomics; Trimethoprim, Sulfamethoxazole Drug Combination; Vaccines, Attenuated

This study was designed to evaluate the safety, immunogenicity, and efficacy of a single dose of L. infantum (LiCen

Topics: Animals; CD8-Positive T-Lymphocytes; Cytokines; Dog Diseases; Dogs; Interleukin-17; Leishmania infantum; Leishmaniasis; Leishmaniasis Vaccines; Leishmaniasis, Visceral; Trimethoprim, Sulfamethoxazole Drug Combination; Vaccines, Attenuated

Topics: Child; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Visceral; Rifampin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

Topics: Administration, Oral; Child; Child, Preschool; Drug Combinations; Female; Follow-Up Studies; Humans; Leishmaniasis, Visceral; Male; Rifampin; Tablets; Trimethoprim, Sulfamethoxazole Drug Combination

Topics: Adult; Antiprotozoal Agents; Drug Combinations; Female; Humans; Leishmaniasis, Visceral; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Topics: Drug Combinations; Female; Humans; Leishmaniasis, Visceral; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Topics: Adult; Drug Combinations; Humans; Leishmaniasis, Visceral; Male; Metronidazole; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination